Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

Stephen T KeirVidyalakshmi ChandramohanCarlee D HemphillMichael M GrandalMaria Carlsen MelanderMikkel W PedersenIvan D HorakMichael KraghAnnick DesjardinsHenry S FriedmanDarell D Bigner

Published in: Journal of neuro-oncology (2018)

These results demonstrate the broad activity of Sym004 in patient-derived EGFRvIII-expressing GBM xenograft models and provide a clear rationale for clinical evaluation of Sym004 in EGFRvIII-positive adult GBM patients.

Keyphrases

end stage renal disease
small cell lung cancer
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
epidermal growth factor receptor
tyrosine kinase
intellectual disability
patient reported outcomes
autism spectrum disorder
oxidative stress